Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab plus R-CHOP versus R-CHOP in newly diagnosed DLBCL
NL-OMON53434Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma (2 arms), sponsored by AbbVie Inc. Primary endpoint: progression-free survival. Started May 2023; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON53434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53434.